AAPL 165.84 0.5091% MSFT 400.96 0.461% GOOG 157.95 1.4321% GOOGL 156.28 1.4212% AMZN 177.23 1.4889% NVDA 795.18 4.3543% META 481.73 0.1372% TSLA 142.05 -3.4002% TSM 129.75 1.6053% LLY 731.33 0.6912% V 272.33 0.9452% AVGO 1224.46 1.6394% JPM 189.41 1.9429% UNH 491.23 -1.9755% NVO 125.26 2.0781% WMT 60.14 1.0247% LVMUY 168.89 0.4222% XOM 120.57 0.5756% LVMHF 851.89 0.4528% MA 456.75 0.2986%

Genmab AS

Healthcare US GMAB


Last update at 2024-04-22T20:00:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 7035.00M 3983.00M 5904.00M 2859.00M 1611.97M
Minority interest - - - 0.00000M 0.00000M
Net income 5522.00M 3008.00M 4758.00M 2166.00M 1472.14M
Selling general administrative 2676.00M 1283.00M 661.00M 342.00M 213.69M
Selling and marketing expenses - - - - -
Gross profit 14595.00M 8482.00M 10111.00M 5366.00M 3025.14M
Reconciled depreciation 362.00M 248.00M 259.00M 139.00M 87.60M
Ebit 6357.00M 3018.00M 6313.00M 2638.00M 1612.39M
Ebitda 7043.00M 3463.00M 6756.00M 2897.00M 1699.98M
Depreciation and amortization 686.00M 445.00M 443.00M 259.00M 87.60M
Non operating income net other - - - 0.00000M 0.00000M
Operating income 6357.00M 3018.00M 6313.00M 2638.00M 1380.28M
Other operating expenses 8238.00M 5464.00M 3798.00M 2728.00M 1644.85M
Interest expense 21.00M 13.00M 10.00M 7.00M 0.42M
Tax provision 1513.00M 975.00M 1146.00M 693.00M 139.83M
Interest income 324.00M 197.00M 184.00M 348.00M 62.92M
Net interest income 303.00M 184.00M 174.00M 334.00M 62.51M
Extraordinary items - - - 0.00000M 0.00000M
Non recurring - - - 0.00000M 0.00000M
Other items - - - 0.00000M 0.00000M
Income tax expense 1513.00M 975.00M 1146.00M 693.00M 139.83M
Total revenue 14595.00M 8482.00M 10111.00M 5366.00M 3025.14M
Total operating expenses 8238.00M 5464.00M 3798.00M 2728.00M 1644.85M
Cost of revenue - - - 0.00000M 0.00000M
Total other income expense net 678.00M 965.00M -409.00000M 221.00M 231.69M
Discontinued operations - - - 0.00000M 0.00000M
Net income from continuing ops 5522.00M 3008.00M 4758.00M 2166.00M 1472.14M
Net income applicable to common shares 5522.00M 3008.00M 4758.00M 2166.00M 1472.00M
Preferred stock and other adjustments - - - 0.00000M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 30278.00M 24627.00M 21143.00M 15144.00M 8461.00M
Intangible assets 146.00M 254.00M 338.00M 470.00M 470.36M
Earning assets - - - - -
Other current assets - - - 10398.00M 0.00000M
Total liab 2837.00M 2431.00M 2022.00M 1096.00M 446.64M
Total stockholder equity 27441.00M 22196.00M 19121.00M 14048.00M 8014.36M
Deferred long term liab - - - 0.00000M 0.00000M
Other current liab 1716.00M 1130.00M 1185.00M 912.00M 443.35M
Common stock 66.00M 66.00M 66.00M 65.00M 61.50M
Capital stock 66.00M 66.00M 66.00M 65.00M 61.50M
Retained earnings 14968.00M 10020.00M 7107.00M 2130.00M -197.45900M
Other liab 491.00M 500.00M 492.00M 3.00M 3.00M
Good will - - - 0.00000M 0.00000M
Other assets 300.00M 291.00M 197.00M 150.00M 396.00M
Cash 9893.00M 8957.00M 7260.00M 3552.00M 532.91M
Cash and equivalents - - - - -
Total current liabilities 1823.00M 1568.00M 1253.00M 938.00M 443.35M
Current deferred revenue 33.00M 26.00M 26.00M - -
Net debt -9296.00000M -8532.00000M -6941.00000M -3371.00000M -532.90700M
Short term debt 74.00M 62.00M 42.00M 26.00M 0.00000M
Short long term debt - - - 0.00000M 0.00000M
Short long term debt total 597.00M 425.00M 319.00M 181.00M 0.00000M
Other stockholder equity 12309.00M 12029.00M 11894.00M 11755.00M 8058.61M
Property plant equipment 1322.00M 975.00M 736.00M 414.00M 162.00M
Total current assets 28377.00M 22736.00M 18791.00M 13961.00M 7433.02M
Long term investments 133.00M 371.00M 1081.00M 149.00M 0.00000M
Net tangible assets 27295.00M 21942.00M 18783.00M 13578.00M 7544.00M
Short term investments 12431.00M 10381.00M 8819.00M 7419.00M 5573.19M
Net receivables 6053.00M 3398.00M 2712.00M 2990.00M 1326.93M
Long term debt - - - 0.00000M 0.00000M
Inventory - - - -10398.00000M 0.00000M
Accounts payable - 350.00M - 0.00000M 0.00000M
Total permanent equity - - - 0.00000M 0.00000M
Noncontrolling interest in consolidated entity - - - 0.00000M 0.00000M
Temporary equity redeemable noncontrolling interests - - - 0.00000M 0.00000M
Accumulated other comprehensive income 98.00M 81.00M 54.00M 98.00M 91.71M
Additional paid in capital - - - 0.00000M 0.00000M
Common stock total equity - - 66.00M 65.00M 61.50M
Preferred stock total equity - - - 0.00000M 0.00000M
Retained earnings total equity - - - 0.00000M 0.00000M
Treasury stock - - - 0.00000M 0.00000M
Accumulated amortization - - - 0.00000M 0.00000M
Non currrent assets other 48.00M 27.00M 20.00M 11.00M 9.62M
Deferred long term asset charges - - - 0.00000M 0.00000M
Non current assets total 1901.00M 1891.00M 2352.00M 1183.00M 1027.97M
Capital lease obligations 597.00M 425.00M 319.00M 181.00M 0.00000M
Long term debt total - - - 155.00M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2761.00000M -709.00000M -2351.00000M -1983.00000M -1777.55300M
Change to liabilities 283.00M 304.00M 681.00M 440.00M 134.00M
Total cashflows from investing activities -2761.00000M -961.00000M -2351.00000M -1983.00000M -1778.00000M
Net borrowings -73.00000M -58.00000M -44.00000M -31.00000M -31.00000M
Total cash from financing activities -789.00000M -420.00000M 71.00M 3660.00M -70.90100M
Change to operating activities - -770.00000M -770.00000M -770.00000M -770.00000M
Net income 7035.00M 3983.00M 5904.00M 2859.00M 1611.97M
Change in cash 936.00M 1697.00M 3708.00M 3019.00M -814.63800M
Begin period cash flow 8957.00M 7260.00M 3552.00M 533.00M 1347.55M
End period cash flow 9893.00M 8957.00M 7260.00M 3552.00M 532.91M
Total cash from operating activities 3912.00M 2228.00M 6433.00M 1326.00M 1014.79M
Issuance of capital stock - 0.00000M 0.00000M 3873.00M 0.31M
Depreciation 362.00M 248.00M 259.00M 139.00M 87.60M
Other cashflows from investing activities - - - -1872.00000M -1300.18700M
Dividends paid - - - 0.00000M 0.00000M
Change to inventory - - - 0.00000M 0.00000M
Change to account receivables -2213.00000M -1074.00000M 306.00M -0.00006M -0.00004M
Sale purchase of stock -908.00000M -447.00000M 0.00000M 0.00000M -146.17500M
Other cashflows from financing activities 192.00M 85.00M 115.00M -182.00000M 74.96M
Change to netincome -78.00000M -314.00000M 422.00M 211.00M 89.00M
Capital expenditures 317.00M 252.00M 307.00M 111.00M 477.37M
Change receivables - - - 0.00000M 0.00000M
Cash flows other operating - - - 0.00000M 0.00000M
Exchange rate changes - - - 0.00000M 0.00000M
Cash and cash equivalents changes - - - 0.00000M 0.00000M
Change in working capital -1930.00000M -770.00000M 987.00M -1218.00000M -634.37200M
Stock based compensation 439.00M 310.00M 200.00M 147.00M 90.76M
Other non cash items -1994.00000M -997.00000M 409.00M -216.00000M -231.68800M
Free cash flow 3595.00M 1976.00M 6126.00M 1215.00M 537.42M


  • Previous Close 28.70
  • Market Cap20201.75M
  • Volume452366
  • P/E Ratio32.21
  • Dividend Yield-%
  • EBITDA6735.00M
  • Revenue TTM17023.00M
  • Revenue Per Share TTM26.07
  • Gross Profit TTM 14595.00M
  • Diluted EPS TTM0.95

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Genmab AS
0.27 0.94% 28.97 32.21 21.32 1.19 4.39 0.95 3.00
Novo Nordisk A/S
2.55 2.08% 125.26 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
3.76 3.07% 126.26 41.06 31.25 2.08 33.11 2.11 4.70
Vertex Pharmaceuticals Inc
5.64 1.43% 399.92 30.40 24.75 10.68 6.25 9.52 20.36
2.35 2.71% 89.17 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News


Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab AS

Kalvebod Brygge 43, Copenhagen, Denmark, 1560

Key Executives

Name Title Year Born
Dr. Jan G.J. van de Winkel Ph.D. Co-Founder, Pres & CEO 1961
Mr. Anthony Pagano Exec. VP & CFO 1978
Mr. Anthony Mancini Exec. VP & COO 1971
Dr. Judith V. Klimovsky M.D. Exec. VP & Chief Devel. Officer 1958
Dr. Tahamtan Ahmadi Exec. VP, Chief Medical Officer & Head of Experimental Medicines 1973
Dr. Mijke Zachariasse Ph.D. Director of Protein Production & Chemist and Non-Independent Director 1974
Dr. Rima Bawarshi Nassar Ph.D. VP, Head of Global Regulatory Affairs ? Oncology & Non-Independent Director 1953
Mr. Peter Ros Sr. Director of Fin. & Accounting NA
Mr. Andrew Carlsen Sr. Director, VP & Head of Investor Relations NA
Ms. Birgitte Stephensen M.Sc. Exec. VP & Chief Legal Officer 1961

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).